XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2
BUSINESS SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, ACOs and DCEs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2022 and 2021.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
        
    As of June 30, 2022, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three and six months ended June 30, 2022 and 2021. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses,
net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2021 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Net revenues:    
DIS business$2,384 $2,474 $4,925 $5,117 
All other operating segments69 76 139 153 
Total net revenues $2,453 $2,550 $5,064 $5,270 
Operating earnings (loss):    
DIS business$442 $601 $1,004 $1,313 
All other operating segments6 9 13 18 
General corporate activities(60)(77)(116)(138)
Total operating income388 533 901 1,193 
Non-operating (expense) income, net(65)284 (126)250 
Income before income taxes and equity in earnings of equity method investees323 817 775 1,443 
Income tax expense(77)(177)(187)(330)
Equity in earnings of equity method investees, net of taxes4 10 35 27 
Net income250 650 623 1,140 
Less: Net income attributable to noncontrolling interests16 19 34 40 
Net income attributable to Quest Diagnostics$234 $631 $589 $1,100 

    Net revenues by major service were as follows:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Routine clinical testing and other services$1,098 $1,150 $2,164 $2,182 
COVID-19 testing services355 511 954 1,339 
Gene-based and esoteric (including advanced diagnostics) testing services787 673 1,526 1,326 
Anatomic pathology testing services144 140 281 270 
All other69 76 139 153 
Total net revenues$2,453 $2,550 $5,064 $5,270